Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 14/20 | 0.43 |
| ▸ | HTR2C | P28335 | 10/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.34 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL2208422 | 0.93 | HTR2B (0.39) | HTR2BHTR2CHTR2AGUCY1A1GUCY1B1 | |
| SCHEMBL12433798 | 0.86 | HTR2B (0.52) | HTR2BHTR2CHTR2A | |
| SCHEMBL12433816 | 0.84 | HTR2C (0.48) | HTR2BHTR2CHTR2ASIGMAR1 | |
| SCHEMBL12433807 | 0.83 | HTR2B (0.44) | HTR2BHTR2CHTR2AADCY10 | |
| SCHEMBL12433792 | 0.81 | HTR2B (0.43) | HTR2BHTR2CHTR2ASIGMAR1 | |
| Succinic Acid SCHEMBL2215481 | 0.80 | HTR2B (0.46) | HTR2BHTR2CHTR2A | |
| SCHEMBL12433791 | 0.79 | HTR2B (0.38) | HTR2BHTR2CHTR2ASIGMAR1 | |
| SCHEMBL12433800 | 0.78 | HTR2B (0.39) | HTR2BHTR2CHTR2ASLC6A2SLC6A4 | |
| Succinic Acid SCHEMBL2208827 | 0.78 | HTR2C (0.42) | HTR2BHTR2CHTR2A | |
| Succinic Acid SCHEMBL2209291 | 0.78 | HTR2B (0.41) | HTR2BHTR2CHTR2AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981882-B2 | e.g. 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine; antidepressant, anxiolytic agent; obesity, obsessive/compulsive disorder | ELI LILLY AND COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981882-B2 | e.g. 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine; antidepressant, anxiolytic agent; obesity, obsessive/compulsive disorder | ELI LILLY AND COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-20080214520-A1 | 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| US-20080214520-A1 | 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214520-A1 | 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR3B, HTR1A | HTR2B 7/4885HTR2C 1/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.